Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study
Portfolio Pulse from Vandana Singh
Cassava Sciences Inc (NASDAQ:SAVA) announced positive results from its Cognition Maintenance Study (CMS) for its Alzheimer's treatment, Simufilam. The drug slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer's disease. The company is currently evaluating Simufilam tablets in two Phase 3 studies, with patient enrollment expected to be completed by the end of 2023. Despite the positive news, SAVA shares are down 12.90% at $22.05.
July 05, 2023 | 4:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cassava Sciences' Alzheimer's drug, Simufilam, showed positive results in a study, but the company's stock price fell by 12.90%.
The positive results from the study of Simufilam, Cassava Sciences' Alzheimer's drug, would typically be expected to boost the company's stock price. However, despite the promising results, the company's stock price fell by 12.90%. This could be due to a variety of factors not mentioned in the article, such as broader market trends or investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100